CN118662440A - 氟碳化合物纳米乳液的组合物及其制备方法和用途 - Google Patents

氟碳化合物纳米乳液的组合物及其制备方法和用途 Download PDF

Info

Publication number
CN118662440A
CN118662440A CN202410295358.5A CN202410295358A CN118662440A CN 118662440 A CN118662440 A CN 118662440A CN 202410295358 A CN202410295358 A CN 202410295358A CN 118662440 A CN118662440 A CN 118662440A
Authority
CN
China
Prior art keywords
mixture
nanoemulsion
glycero
pressure vessel
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410295358.5A
Other languages
English (en)
Chinese (zh)
Inventor
E·C·昂格尔
E·R·玛利尼里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvox Pharma LLC
Original Assignee
Nuvox Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvox Pharma LLC filed Critical Nuvox Pharma LLC
Publication of CN118662440A publication Critical patent/CN118662440A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L27/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers
    • C08L27/02—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment
    • C08L27/12—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CN202410295358.5A 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途 Pending CN118662440A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562270226P 2015-12-21 2015-12-21
US62/270,226 2015-12-21
PCT/US2016/067650 WO2017112614A1 (en) 2015-12-21 2016-12-20 Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
CN201680081126.3A CN108697664A (zh) 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680081126.3A Division CN108697664A (zh) 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN118662440A true CN118662440A (zh) 2024-09-20

Family

ID=59089857

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410295358.5A Pending CN118662440A (zh) 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途
CN201680081126.3A Pending CN108697664A (zh) 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680081126.3A Pending CN108697664A (zh) 2015-12-21 2016-12-20 氟碳化合物纳米乳液的组合物及其制备方法和用途

Country Status (11)

Country Link
US (3) US11304899B2 (https=)
EP (1) EP3393459A4 (https=)
JP (1) JP6936226B2 (https=)
KR (2) KR20240100472A (https=)
CN (2) CN118662440A (https=)
AU (2) AU2016377361B2 (https=)
BR (1) BR112018012618A2 (https=)
CA (1) CA3009404C (https=)
EA (1) EA201891296A1 (https=)
IL (2) IL298236B2 (https=)
WO (1) WO2017112614A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102342324B1 (ko) * 2020-12-11 2021-12-23 애경케미칼주식회사 불소계 계면활성제 조성물
KR102342326B1 (ko) * 2020-12-11 2021-12-23 애경케미칼주식회사 계면장력이 우수한 불소계 계면활성제 조성물
WO2024227100A1 (en) * 2023-04-26 2024-10-31 Swaza Inc. Nanoparticle composition for oxygen delivery
CN116622338A (zh) * 2023-06-05 2023-08-22 西安科技大学 井下复合型降尘防爆一体化处理材料及其制备方法和应用
WO2025143844A1 (ko) * 2023-12-27 2025-07-03 (주)아이엠디팜 과불화탄소와 카제인을 함유한 산소운반체 약학조성물 및 그의 제조방법
KR20260008977A (ko) 2024-07-10 2026-01-19 강원대학교산학협력단 키토산-운데칸산 나노에멀젼 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP3616691A1 (en) * 2011-03-04 2020-03-04 The Board of Trustees of the University of Arkansas Dodecafluoropentane emulsion as a stroke and ischemia therapy
US10279053B2 (en) * 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same
WO2013043236A1 (en) * 2011-09-22 2013-03-28 Rockland Technimed, Ltd. Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism
US8822549B2 (en) * 2011-10-13 2014-09-02 Jennifer L. Johnson Buffered oxygen therapeutic
CN113398070A (zh) * 2014-03-05 2021-09-17 埃文·C·昂格尔 利用氧气疗法的分割放疗和化疗
US9801959B2 (en) * 2014-06-12 2017-10-31 Microvascuar Therapeutics Llc Phospholipid composition and microbubbles and emulsions formed using same
EP3233136B8 (en) * 2014-12-18 2019-04-10 Bracco Suisse SA Targeted gas-filled microvesicles formulation

Also Published As

Publication number Publication date
IL260206B (en) 2022-12-01
EA201891296A1 (ru) 2019-01-31
AU2022235555A1 (en) 2022-10-13
IL298236A (en) 2023-01-01
US20180360754A1 (en) 2018-12-20
WO2017112614A1 (en) 2017-06-29
CA3009404C (en) 2023-12-12
IL260206A (en) 2018-07-31
IL260206B2 (en) 2023-04-01
KR20180132605A (ko) 2018-12-12
IL298236B2 (en) 2024-05-01
CN108697664A (zh) 2018-10-23
US11304899B2 (en) 2022-04-19
EP3393459A1 (en) 2018-10-31
EP3393459A4 (en) 2019-10-02
US20250248937A1 (en) 2025-08-07
AU2016377361A1 (en) 2018-07-05
KR102679118B1 (ko) 2024-06-26
US20220401364A1 (en) 2022-12-22
CA3009404A1 (en) 2017-06-29
AU2022235555B2 (en) 2024-11-14
BR112018012618A2 (pt) 2018-12-04
JP2019502682A (ja) 2019-01-31
IL298236B1 (en) 2024-01-01
AU2016377361B2 (en) 2022-07-07
JP6936226B2 (ja) 2021-09-15
KR20240100472A (ko) 2024-07-01

Similar Documents

Publication Publication Date Title
AU2022235555B2 (en) Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
KR101910213B1 (ko) 부분불소화된 알칸을 포함하는 수중유형 에멀젼
JP5668004B2 (ja) ２，６−ジイソプロピルフェノール（プロポフォール）の水性医薬組成物およびその使用
CN101917970A (zh) 复苏液
EA010242B1 (ru) Препарат микроэмульсии с высокой концентрацией пропофола для анестезирующих применений
US20140023718A1 (en) Prostaglandin-containing fat emulsion
AU717321B2 (en) Reverse gels comprising a continuous fluorinated phase
CN101553215B (zh) 稳定的即用型水包油丙泊酚微乳液
EA040209B1 (ru) Способ получения водной фторуглеродной наноэмульсии
RU2240108C1 (ru) Эмульсия перфторорганических соединений с газотранспортными свойствами
RU2329788C2 (ru) Перфторуглеродно-жировые эмульсии с газотранспортными и энергетическими свойствами для медицинского назначения: состав, способ получения и средство для лечения
CN108888594A (zh) 静脉注射给药的纳米脂肪乳剂
HK1135029B (en) Stable and ready-to-use oil-in-water propofol microemulsion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination